Clinical Trial Update: Antiangiogenic Peptide Vaccine Therapy in Treating Patient With Hepatocellular Carcinoma [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating an antiangiogenic peptide vaccine for hepatocellular carcinoma, sponsored by Fukushima Medical University.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• antiangiogenic peptide vaccine therapy

Snippet

Sponsor: Fukushima Medical University | Conditions: Hepatocellular Carcinoma | Phase 1 | Status: UNKNOWN